This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
Join us for an exclusive online teaching session led by the renowned Professor Arun Sanyal, M.D., the leading global expert in liver diseases, including MASH (Metabolic Associated Steatohepatitis). This session is specifically designed for physicians and healthcare professionals involved in the care of patients with MASH and metabolic syndrome.
This session is part of a six part series presented by global MASH experts.
Session Overview
In this session, Professor Sanyal will provide in-depth insights into the emerging role of GLP-1 (Glucagon-Like Peptide-1) in the treatment of MASH and associated metabolic syndrome. Participants will have the opportunity to gain a comprehensive understanding of the latest developments in this rapidly evolving field.
Incorporate New Insights on GLP-1:
Learn about the latest updates in the role of GLP-1 in managing MASH and metabolic syndrome and how the latest advances in GLP-1-based therapies can be integrated into patient care to improve outcomes.
Understand and Communicate the Mechanism of Action:
Gain a deeper understanding of the mechanisms by which GLP-1 influences metabolic processes and MASH progression. Gain the ability to communicate these mechanisms effectively to patients and colleagues.
Critically Evaluate Latest Research and Clinical Trials:
Engage with the most recent research findings and clinical trial results on GLP-1-related therapies. Learn to apply the evidence to optimize patient treatment plans, in alignment with the American Association for the Study of Liver Diseases (AASLD) guidelines.
Presented by Professor Arun Sanyal
Professor Arun Sanyal, M.D., is a distinguished Professor of Medicine, Physiology, and Molecular Pathology at Virginia Commonwealth University, with over 25 years of expertise in hepatology. He leads the NIH NASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum, focusing on liver diseases like NAFLD and NASH, and their complications. Dr. Sanyal has made significant contributions to the field, authoring over 350 research articles in top medical journals and shaping national practice guidelines. His leadership roles include serving as president of the American Association for the Study of Liver Diseases and on numerous advisory boards. A recipient of multiple prestigious awards, Dr. Sanyal continues to impact global liver disease management and research, supported by continuous NIH funding since 1995.
Who is this course for
This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:
✅ Gastroenterologists
✅ Hepatologists
✅ Primary Care Physicians
✅ Endocrinologists
✅ Cardiologists
✅ Nurse Practitioners
✅ Physician Assistants
✅ Dietitians/Nutritionists
✅ Pharmacists
✅ Other Health Professionals
Continuing Education Information
This continuing education activity is provided by AffinityCE and MedAll. This activity provides continuing education credit for physicians, physician assistants, nurses, and nurse practitioners and pharmacists. A statement of participation is available to other attendees.
Learning Objectives
At the completion of this activity, participants should be able to:
Incorporate new insights on the role of GLP-1 in the treatment of MASH and metabolic syndrome:
- Understand and communicate the mechanism of action of GLP-1 and its potential impact on MASH management.
- Critically evaluate and integrate findings from the latest research and clinical trials on GLP--related therapies into patient treatment plans, adhering to AASLD guidelines for patients with comorbid conditions.
Faculty
Arun J. Sanyal, M.D.
Professor, Director of Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, School of Medicine - Internal Medicine - Virginia Commonwealth University
Tony Villiotti
Patient Advocate
Faculty Disclosures
Arun J. Sanyal
Consultant: 89 Bio, Abbott, Akero, Alnylam, Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade, Corcept, Echosens, Eli Lilly and Company, Foresite, Gatehouse, Genentech, Genfit, Gilead, Glaxo-Smith Kline, Histoindex, Intercept, Inventiva, Janssen, Lipocine, Madrigal, Malinckrodt, Median technologies, Merck, Mitopower, Myovant, Novartis, Novo Nordisk, Path AI, Pfizer, Poxel, Promed, Regeneron, Rivus, Salix, Satellite Bio, Sequana, Siemens, Surrozen, Takeda, Terns, Thera Technologies, Variant, Zydus
Institute has received grant support from AstraZeneca, Boehringer Ingelhiem, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead, Intercept, Inventiva, Mallinckrodt, Merck, Novartis, Novo Nordisk, Ocelot and Salix.
Royalties from Elseiver and UpToDate. He has stock options in Inversago, Durect, Genfit, Exhalenz, Northsea, Rivus and Tiziana.
Intends to discuss non-FDA uses of drug products and/or devices and their unlabeled indications. The discussion relates to GLP-1 in the context of MASH and will be disclosed to the audience when this discussion takes place.
Tony Villiotti
Consultant: Madrigal Pharmaceuticals & Regeneron.
No unapproved product related discussions to disclose.
Disclosures
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Continuing Nursing Education is provided for this program through the joint providership between MedAll and AffinityCE. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This live activity provides a maximum of 1.5 hours of continuing nursing education credit.
Criteria for Claiming CNE Credit: Participants must have registered and attended the entire program. Attendance is monitored online for participation in the entire activity.
Pharmacists AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).
CE Title: Incorporating new insights on the role of GLP-1 in the treatment of MASH and metabolic syndrome
UAN: 0829-9999-24-374-L01-P
Activity Type: Knowledge-based
CEUs: 1.5
No cost to participate.
Participant CE records will be electronically communicated to CPE Monitor.
Pharmacist Learning Objectives
At the conclusion of this web conference, participants should be able to:
- Recognize the new insights on the role of GLP-1 in the treatment of MASH and metabolic syndrome
- Review the mechanism of action of GLP-1 and its potential impact on MASH management
- Evaluate and integrate findings from the latest research and clinical trials on GLP--related therapies into patient treatment plans, adhering to AASLD guidelines for patients with co-morbid conditions
Criteria for Claiming CPE Credit: Participants must have registered and attended the entire program. Attendance is monitored online for participation in the entire activity.
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
How to Earn CE Credit
At the end of the live session participants will be sent an email with a feedback form. On completion of the feedback form participants with be issued a certificate with their CE credit.
How to Earn CE Credit: Pharmacists Only
Diagnostic Updates in Metabolic Dysfunction-Associated Steatohepatitis
Registration for the Activity does not establish an account in the CE Center or automatically provide continuing education credit. You must sign into the CE Center site and evaluate the content of the activity to earn CE credit.
1.Please use the private evaluation link provided to you to access the CE Center.
IMPORTANT: You must use this link every time you access the CE Center for this activity.
2. Select the activity: Identifying Complications in Metabolic Dysfunction-Associated Steatohepatitis
3. Enter an e-mail address and password to begin setting up your profile. Select “I Forgot My Password” if you need to reset the password you set up.
4. Verify, correct, or add your information.
5. Participants claiming Pharmacist CE credits will need to supply their Date of birth and NABP e-Profile ID. Pharmacy CE records will be electronically communicated to CPE Monitor.
6. Complete the post-activity evaluation after attending the entire program.
7. After completing the activity evaluation, you will be able to download your CE certificate. Your CE record will also be stored here for later retrieval.
8. The website is open for completing your evaluation until July 24, 2024.
9. After the website has closed, you can come back to the site at any time to download your certificate, but you will not be able to add any evaluations.Please send any customer service requests to cds_support+medall@affinityced.com.